Study for CLDN18.2-positive advanced gut cancers after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a combination anti-cancer medicine (LM-302) plus other anti-tumor treatments for advanced gastrointestinal cancers. It’s designed for people whose tumors test positive for CLDN18.2 and who have already tried standard first-line treatment but didn’t respond or couldn’t tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 80 and willing to sign informed consent before any study tests.
- Advanced gastrointestinal cancer confirmed by pathology (biopsy), and you’ve had first-line standard treatment that failed or you couldn’t tolerate it.
- Your tumor must test positive for CLDN18.2.
- You can do daily activities fairly normally (ECOG performance status 0–1) and have at least 3 months expected survival.
- You must have at least one measurable tumor spot on scans, and your blood/organ function must be within required ranges on labs taken within 7 days before the first dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This trial tests a new drug, LM-302, combined with gemcitabine for people with a specific type of advanced pancreatic cancer that has not responded to or stopped working on first-line treatment. The goal is to see if the combination is safe and effective.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Hear when a new Malignant Neoplasms of Digestive Organs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.